{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:35:21Z","timestamp":1789504521988,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mass drug administration (MDA) is the cornerstone for the elimination of lymphatic filariasis (LF). The proportion of the population that is never treated (NT) is a crucial determinant of whether this goal is achieved within reasonable time frames.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using 2 individual-based stochastic LF transmission models, we assess the maximum permissible level of NT for which the 1% microfilaremia (mf) prevalence threshold can be achieved (with 90% probability) within 10 years under different scenarios of annual MDA coverage, drug combination and transmission setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For Anopheles-transmission settings, we find that treating 80% of the eligible population annually with ivermectin + albendazole (IA) can achieve the 1% mf prevalence threshold within 10 years of annual treatment when baseline mf prevalence is 10%, as long as NT &amp;lt;10%. Higher proportions of NT are acceptable when more efficacious treatment regimens are used. For Culex-transmission settings with a low (5%) baseline mf prevalence and diethylcarbamazine + albendazole (DA) or ivermectin + diethylcarbamazine + albendazole (IDA) treatment, elimination can be reached if treatment coverage among eligibles is 80% or higher. For 10% baseline mf prevalence, the target can be achieved when the annual coverage is 80% and NT \u226415%. Higher infection prevalence or levels of NT would make achieving the target more difficult.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The proportion of people never treated in MDA programmes for LF can strongly influence the achievement of elimination and the impact of NT is greater in high transmission areas. This study provides a starting point for further development of criteria for the evaluation of NT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae021","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:31:56Z","timestamp":1714062716000},"page":"S93-S100","source":"Crossref","is-referenced-by-count":15,"title":["How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?"],"prefix":"10.1093","volume":"78","author":[{"given":"Klodeta","family":"Kura","sequence":"first","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research , London , United Kingdom"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London , London , United Kingdom"},{"name":"MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma A","family":"Stolk","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Gloria","family":"Bas\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research , London , United Kingdom"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London , London , United Kingdom"},{"name":"MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S","family":"Collyer","sequence":"additional","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research , London , United Kingdom"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London , London , United Kingdom"},{"name":"MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sake J","family":"de Vlas","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Diggle","sequence":"additional","affiliation":[{"name":"Centre for Health Informatics, Computing and Statistics, Lancaster University , Lancaster , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gass","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases Support Center, Task Force for Global Health , Decatur, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Graham","sequence":"additional","affiliation":[{"name":"Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford , Oxford , United Kingdom"},{"name":"Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T D\u00e9irdre","family":"Hollingsworth","sequence":"additional","affiliation":[{"name":"Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford , Oxford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"King","sequence":"additional","affiliation":[{"name":"Department of Control of Neglected Tropical Diseases, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Krentel","sequence":"additional","affiliation":[{"name":"Bruy\u00e8re Research Institute , Canada"},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy M","family":"Anderson","sequence":"additional","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research , London , United Kingdom"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London , London , United Kingdom"},{"name":"MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc E","family":"Coffeng","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024042516221472400_ciae021-B1","author":"World Health Organization"},{"key":"2024042516221472400_ciae021-B2","doi-asserted-by":"crossref","first-page":"e1366","DOI":"10.1371\/journal.pntd.0001366","article-title":"The emerging story of disability associated with lymphatic filariasis: a critical review","volume":"5","author":"Zeldenryk","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S0031182000066646","article-title":"Re-assessing the global prevalence and distribution of lymphatic filariasis","volume":"112","author":"Michael","year":"1996","journal-title":"Parasitology"},{"key":"2024042516221472400_ciae021-B4","doi-asserted-by":"crossref","first-page":"e0004397","DOI":"10.1371\/journal.pntd.0004397","article-title":"Productivity loss related to neglected tropical diseases eligible for preventive chemotherapy: a systematic literature review","volume":"10","author":"Lenk","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B5"},{"key":"2024042516221472400_ciae021-B6","volume-title":"Global programme to eliminate lymphatic filariasis: a manual for national elimination programmes","author":"WHO","year":"2011"},{"key":"2024042516221472400_ciae021-B7"},{"key":"2024042516221472400_ciae021-B8","doi-asserted-by":"crossref","first-page":"e0005163","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B9","author":"World Health Organization"},{"key":"2024042516221472400_ciae021-B10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.epidem.2017.02.002","article-title":"Measuring and modelling the effects of systematic non-adherence to mass drug administration","volume":"18","author":"Dyson","year":"2017","journal-title":"Epidemics"},{"key":"2024042516221472400_ciae021-B11"},{"key":"2024042516221472400_ciae021-B12"},{"key":"2024042516221472400_ciae021-B13","doi-asserted-by":"crossref","first-page":"e0006426","DOI":"10.1371\/journal.pntd.0006426","article-title":"Ensuring no one is left behind: urgent action required to address implementation challenges for NTD control and elimination","volume":"12","author":"Krentel","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B14","first-page":"26","article-title":"Accelerating the uptake of WHO recommendations for mass drug administration using ivermectin, diethylcarbamazine, and albendazole","volume":"106","author":"King","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"2024042516221472400_ciae021-B15","doi-asserted-by":"crossref","first-page":"e0009002","DOI":"10.1371\/journal.pntd.0009002","article-title":"A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis","volume":"15","author":"Krentel","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B16","doi-asserted-by":"crossref","first-page":"e2447","DOI":"10.1371\/journal.pntd.0002447","article-title":"A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis","volume":"7","author":"Krentel","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s13071-015-1152-3","article-title":"Modelling strategies to break transmission of lymphatic filariasis\u2014aggregation, adherence and vector competence greatly alter elimination","volume":"8","author":"Irvine","year":"2015","journal-title":"Parasit Vectors"},{"key":"2024042516221472400_ciae021-B18","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciy003","article-title":"Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models","volume":"66","author":"Stolk","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024042516221472400_ciae021-B19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13071-017-2206-5","article-title":"The importance of patient compliance in repeated rounds of mass drug administration (MDA) for the elimination of intestinal helminth transmission","volume":"10","author":"Farrell","year":"2017","journal-title":"Parasit Vectors"},{"key":"2024042516221472400_ciae021-B20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s13071-015-1235-1","article-title":"Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases","volume":"8","author":"Hollingsworth","year":"2015","journal-title":"Parasit Vectors"},{"key":"2024042516221472400_ciae021-B21","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198545996.001.0001","volume-title":"Infectious diseases of humans: dynamics and control","author":"Anderson","year":"1991"},{"key":"2024042516221472400_ciae021-B22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024042516221472400_ciae021-B23","doi-asserted-by":"crossref","first-page":"e0005206","DOI":"10.1371\/journal.pntd.0005206","article-title":"Making transmission models accessible to end-users: the example of TRANSFIL","volume":"11","author":"Irvine","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0038-1634505","article-title":"The LYMFASIM simulation program for modeling lymphatic filariasis and its control","volume":"37","author":"Plaisier","year":"1998","journal-title":"Methods Inf Med"},{"key":"2024042516221472400_ciae021-B25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1017\/S0031182008000437","article-title":"LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages","volume":"135","author":"Stolk","year":"2008","journal-title":"Parasitology"},{"key":"2024042516221472400_ciae021-B26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0031182004004822","article-title":"The dynamics of wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India","volume":"128","author":"Subramanian","year":"2004","journal-title":"Parasitology"},{"key":"2024042516221472400_ciae021-B27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0169-4758(00)01691-4","article-title":"Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection","volume":"16","author":"Plaisier","year":"2000","journal-title":"Parasitol Today"},{"key":"2024042516221472400_ciae021-B28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/trstmh\/trab004","article-title":"Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies","volume":"115","author":"Prada","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024042516221472400_ciae021-B29","doi-asserted-by":"crossref","first-page":"e1000324","DOI":"10.1371\/journal.pmed.1000324","article-title":"Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies","volume":"7","author":"Griffin","year":"2010","journal-title":"PLoS Med"},{"key":"2024042516221472400_ciae021-B30","doi-asserted-by":"crossref","first-page":"e0009596","DOI":"10.1371\/journal.pntd.0009596","article-title":"Assessing factors influencing communities\u2019 acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana","volume":"15","author":"Niles","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B31","doi-asserted-by":"crossref","first-page":"e0005027","DOI":"10.1371\/journal.pntd.0005027","article-title":"Improving coverage and compliance in mass drug administration for the elimination of LF in two \u201cendgame\u201d districts in Indonesia using micronarrative surveys","volume":"10","author":"Krentel","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B32","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4269\/ajtmh.2007.77.1069","article-title":"The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt","volume":"77","author":"El-Setouhy","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2024042516221472400_ciae021-B33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13071-016-1311-1","article-title":"Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review","volume":"9","author":"Shuford","year":"2016","journal-title":"Parasit Vectors"},{"key":"2024042516221472400_ciae021-B34","doi-asserted-by":"crossref","first-page":"e0003642","DOI":"10.1371\/journal.pntd.0003642","article-title":"Elimination of lymphatic filariasis in the Gambia","volume":"9","author":"Rebollo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516221472400_ciae021-B35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s13071-019-3612-7","article-title":"Human population movement can impede the elimination of soil-transmitted helminth transmission in regions with heterogeneity in mass drug administration coverage and transmission potential between villages: a metapopulation analysis","volume":"12","author":"Vegvari","year":"2019","journal-title":"Parasit Vectors"},{"key":"2024042516221472400_ciae021-B36","doi-asserted-by":"crossref","first-page":"e2079","DOI":"10.1371\/journal.pntd.0002079","article-title":"Population migration: implications for lymphatic filariasis elimination programmes","volume":"7","author":"Ramaiah","year":"2013","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/Supplement_2\/S93\/57334410\/ciae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/Supplement_2\/S93\/57334410\/ciae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:32:14Z","timestamp":1714062734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/Supplement_2\/S93\/7657839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":36,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae021","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2024,4,25]]}}}